Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 106

Related Citations for PubMed (Select 23520376)

1.

Pancreatitis associated with incretin-based therapies.

Iyer SN, Tanenberg RJ, Mendez CE, West RL, Drake AJ 3rd.

Diabetes Care. 2013 Apr;36(4):e49. doi: 10.2337/dc12-1987. No abstract available.

2.

[Treatment with new preparations against type 2 diabetes not sufficiently documented].

Karlsson EA, Palmér M, Malmström R.

Lakartidningen. 2008 Feb 27-Mar 4;105(9):647-8; author reply 648-9. Swedish. No abstract available.

PMID:
18376713
3.

Journal withdraws article after complaints from drug manufacturers.

Hawkes N.

BMJ. 2011 Apr 11;342:d2335. doi: 10.1136/bmj.d2335. No abstract available.

PMID:
21482597
4.

[Therapeutic use and adverse events of incretin-related drugs].

Ishikawa M, Yamada Y.

Nihon Rinsho. 2012 May;70 Suppl 3:699-702. Japanese. No abstract available.

PMID:
22768601
5.

[Reply on new drugs against type 2 diabetes: important to gain experience and knowledge].

Sjöholm A, Agardh CD, Brismar K, Efendic S, Eliasson B, Eriksson JW, Frid A, Groop L, Holmgren J, Ridderstråle M, Smith U.

Lakartidningen. 2008 Apr 23-May 6;105(17-18):1310, 1312. Swedish. No abstract available.

PMID:
18561535
6.

An analysis of characteristics of subjects examined for incretin effects on pancreatic pathology.

Harja E, Lord J, Skyler JS.

Diabetes Technol Ther. 2013 Aug;15(8):609-18. doi: 10.1089/dia.2013.0177. Epub 2013 Aug 8.

PMID:
23927624
7.

Two drugs for type 2 diabetes seem to raise risk of acute pancreatitis, study shows.

Cohen D.

BMJ. 2013 Feb 27;346:f1304. doi: 10.1136/bmj.f1304. No abstract available.

PMID:
23447395
8.
9.

Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.

Mikhail N.

Expert Opin Investig Drugs. 2008 Jun;17(6):845-53. doi: 10.1517/13543784.17.6.845 . Review.

PMID:
18491986
10.

Pro- or anti-inflammatory properties of the adipokine dipeptidyl peptidase-4?

Xu L, Spinas GA, Niessen M.

Gastroenterology. 2011 Dec;141(6):e17. doi: 10.1053/j.gastro.2011.08.053. Epub 2011 Oct 27. No abstract available.

PMID:
22036848
11.

GLP-1-based therapies: the dilemma of uncertainty.

Spranger J, Gundert-Remy U, Stammschulte T.

Gastroenterology. 2011 Jul;141(1):20-3. doi: 10.1053/j.gastro.2011.05.019. No abstract available.

PMID:
21723985
12.

Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide.

Dore DD, Seeger JD, Arnold Chan K.

Curr Med Res Opin. 2009 Apr;25(4):1019-27. doi: 10.1185/03007990902820519 .

PMID:
19278373
13.

Case report of acute necrotizing pancreatitis associated with combination treatment of sitagliptin and exenatide.

Iyer SN, Drake AJ 3rd, West RL, Mendez CE, Tanenberg RJ.

Endocr Pract. 2012 Jan-Feb;18(1):e10-3. doi: 10.4158/EP11264.CR.

14.
15.

Exenatide and sitagliptin: pancreatitis and pancreatic cancer. Harms on the rise.

[No authors listed]

Prescrire Int. 2011 Nov;20(121):267. No abstract available.

PMID:
22066314
16.

Treatment of type 2 diabetes mellitus and the incretin system.

Whitehill D.

S D Med. 2007 May;60(5):197, 199. No abstract available.

PMID:
17694940
17.
18.

A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes.

Fakhoury WK, Lereun C, Wright D.

Pharmacology. 2010;86(1):44-57. doi: 10.1159/000314690. Epub 2010 Jul 12. Review.

19.

Exenatide and rare adverse events.

Ahmad SR, Swann J.

N Engl J Med. 2008 May 1;358(18):1970-1; discussion 1971-2. No abstract available.

PMID:
18456920
20.

[The value of incretin based therapies].

Gallwitz B.

Dtsch Med Wochenschr. 2009 May;134(20):1062-6. doi: 10.1055/s-0029-1222570. Epub 2009 May 6. Review. German. No abstract available.

PMID:
19421931
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk